AARD
Aardvark Therapeutics, Inc.
$7.60
+2.60 (+52.00%)
At close · Jul 10
Market Cap
$165.80M
Shares
21,816,385
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2025
Net Income
-$57.59M
FY2025
Diluted EPS
-$2.93
FY2025
Operating Cash Flow
-$54.17M
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 |
|---|---|---|
| — | $0 | |
| $4.85M | $5.14M | |
| $57.75M | $48.94M | |
| $16.97M | $13.79M | |
| — | $36K | |
| $74.72M | $62.73M | |
| -$74.72M | -$62.73M | |
| — | -$62.69M | |
| $4.85M | $5.13M | |
| — | $0 | |
| -$69.87M | -$57.59M | |
| -$69.9M | -$57.51M | |
| USD/shares | — | -$2.93 |
| USD/shares | — | -$2.93 |
| shares | — | 19.62M |
| shares | — | 19.62M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.52×